Study of MK-8353 + Selumetinib in Advanced/Metastatic Solid Tumours (MK-8353-014)

Official Title

Phase 1b Open-label Study of MK-8353 in Combination With Selumetinib (MK-5618) in Participants With Advanced/Metastatic Solid Tumours

Summary:

This is a multicentre, worldwide, open-label study of MK-8353 in combination with selumetinib in participants with histologically or cytologically confirmed diagnosis of advanced solid tumour. This study will evaluate the safety, tolerability, and preliminary efficacy of MK-8353 in combination with selumetinib.

Trial Description

Primary Outcome:

  • Number of Participants with a Dose Limiting Toxicity (DLT)
  • Number of Participants with one or more Adverse Events (AEs)
  • Number of Participants with a Study Drug Discontinuations due to an AE
Secondary Outcome:
  • Area Under the Plasma Concentration-Time Curve (AUC) for MK-8353
  • Minimum Observed Plasma Concentration (Cmin) for MK-8353
  • Maximum Observed Plasma Concentration (Cmax) for MK-8353
  • AUC for Selumetinib
  • Cmin for Selumetinib
  • Cmax for Selumetinib

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.

Resources

Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society